The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US

被引：0
|
作者：
Buthainah Ghanem
Lu Shi
机构：
[1] Chapman University,Department of Pharmaceutical Economics and Policy, School of Pharmacy
[2] Oregon State University,College of Public Health and Human Sciences
来源：
BioDrugs | 2022年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：773 / 780
页数：7
相关论文
共 50 条
  • [41] Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: real-world experience
    Hansen, Doris
    Sidana, Surbhi
    Peres, Lauren
    Leitzinger, Christelle Colin
    Shune, Leyla
    Shrewsbury, Alexandria
    Gonzalez, Rebecca
    Sborov, Douglas
    Wagner, Charlotte
    Hashmi, Hamza
    Kocoglu, Mehmet
    Atrash, Shebli
    Simmons, Gary
    Kalariya, Nilesh
    Ferreri, Christopher
    Afrough, Aimaz
    Kansagra, Ankit
    Voorhees, Peter
    Baz, Rachid
    Khouri, Jack
    Alsina, Melissa
    McGuirk, Joseph
    Locke, Frederick
    Patel, Krina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S2 - S3
  • [42] EVALUATION OF HEALTH STATUS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), CAR T CELL THERAPY AGAINST BCMA
    Paula, Rodriguez-Otero
    Michel, Delforge
    Nina, Shah
    Parames-Waran, Hari
    Julia, Braverman
    Andrew, Trigg
    Payal, Patel
    Liping, Huang
    Kristen, Hege
    Sujith, Dhanasiri
    HAEMATOLOGICA, 2021, 106 (10) : 287 - 288
  • [43] Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma CAR T Consortium Real World Experience
    Khouri, Jack
    Li, Hong
    Hansen, Doris K.
    Sidana, Surbhi
    Shune, Leyla O.
    DeJarnette, Shaun
    Anwer, Faiz
    Sborov, Douglas W.
    Wagner, Charlotte B.
    Kocoglu, M. Hakan
    Atrash, Shebli
    Voorhees, Peter M.
    Valent, Jason
    Peres, Lauren C.
    Hovanky, Vanna
    Simmons, Gary
    Dima, Danai
    Kalariya, Nilesh
    Afrough, Aimaz
    Kaur, Gurbakhash
    Sannareddy, Aishwarya
    Ferreri, Christopher J.
    Davis, James
    McGuirk, Joseph P.
    Locke, Frederick L.
    Baz, Rachid C.
    Hamilton, Betty K.
    Alsina, Melissa
    Sauter, Craig S.
    Hashmi, Hamza
    Patel, Krina
    BLOOD, 2022, 140 : 10427 - 10429
  • [44] Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/ Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation
    John, Lukas
    Sauer, Sandra
    Hegenbart, Ute
    Dreger, Peter
    Hundemer, Michael
    Mueller-Tidow, Carsten
    Schmitt, Anita
    Schmitt, Michael
    Raab, Marc S.
    Schoenland, Stefan O.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (10): : 609.e1 - 609.e6
  • [45] Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
    Berdeja, Jesus G.
    Cohen, Adam D.
    Martin, Thomas
    Madduri, Deepu
    Pacaud, Lida
    Jagannath, Sundar
    FUTURE ONCOLOGY, 2023, 19 (18) : 1235 - 1247
  • [46] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Einsele, Hermann
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    Munshi, Nikhil C.
    Oriol, Albert
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
  • [47] Ciltacabtagene autoleucel CAR-T therapy targeting B-cell maturation antigen (BCMA) Treatment of multiple myeloma
    Lee, Sarah
    Cowan, Andrew J.
    DRUGS OF THE FUTURE, 2022, 47 (04) : 233 - 238
  • [48] Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma
    Derman, Benjamin A.
    Parker, William F.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (08): : 687 - 688
  • [49] Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma
    Mobascher, Paul
    Engelhardt, Monika
    Waesch, Ralph
    ANNALS OF HEMATOLOGY, 2025,
  • [50] Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
    Hashmi, Hamza
    Hansen, Doris K.
    Peres, Lauren C.
    Puglianini, Omar Castaneda
    Freeman, Ciara
    De Avila, Gabriel
    Sidana, Surbhi
    Shune, Leyla
    Sborov, Douglas W.
    Davis, James
    Wagner, Charlotte
    Kocoglu, Mehmet H.
    Atrash, Shebli
    Voorhees, Peter
    Simmons, Gary
    Ferreri, Christopher
    Kalariya, Nilesh
    Anderson, Larry D., Jr.
    Afrough, Aimaz
    Dima, Danai
    Khouri, Jack
    McGuirk, Joseph
    Locke, Frederick L.
    Baz, Rachid
    Patel, Krina K.
    Alsina, Melissa
    HAEMATOLOGICA, 2024, 109 (05) : 1514 - 1524
12345